Home›Screener›ELVN›Profile
D
36/100

Enliven Therapeutics

ELVNPrecision Oncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Enliven Therapeutics (ELVN) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[2], including 4 Phase 1[1].

ELVN has 2 Form 4 insider filings recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR · 0001672619 (2026-04-11) ↗
🔬
Clinical Trials
4
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06787144CML (Chronic Myelogenous Leukemia), Chronic Phase CML
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
2 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Precision Oncology)
IDYAIDEAYA Biosciences
D
RLAYRelay Therapeutics
D
RVMDRevolution Medicines
F
Data Provenance
cik1 verified
clinical trial4 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR